ClinicalTrials.gg
Enrolling by invitationNCT07611019Updated Nov 17, 2026

Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial

A Phase 2/3 interventional study of Colchicine 0.5 MG oral tablet twice daily and Placebo Oral Tablet in Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG), sponsored by National Taiwan University Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Taiwan University Hospital · Phase 2/3, Interventional, and Prevention

How we know

Updated Nov 17, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies testing colchicine in Inflammation — 15 open to participants now, 18 under way, 8 of them phase 3. Colchicine · Inflammation.

Planned enrollment
5th of 35
400 · median 150
Started
2026
with 4 others
Phase 2/3
3 of 35
2 open now
Primary completion
2028-12
later than 15 of 17 live
Registered
32nd of 35
by date

Among the 35 studies testing colchicine in Inflammation, this one is the 5th largest by planned enrollment, is one of 5 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 15 of the 17 other live ones, and was the 32nd registered.

Inflammation

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

Browse Inflammation studies →

Open to participants now

15 of the 35 studies testing colchicine in Inflammation are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing colchicine in Inflammation, or all of them as a file.
02

Study summary

Post-operative atrial fibrillation after coronary artery bypass grafting (CABG)

Read the detailed description

This single-center, prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy of colchicine in preventing post-operative atrial fibrillation (POAF) following coronary artery bypass grafting (CABG) and to compare its pharmacologic and clinical effects between different surgical strategies - off-pump CABG (OPCAB) and on-pump CABG (ONCAB).

Post-operative atrial fibrillation is one of the most common arrhythmias after CABG, with an incidence of approximately 50%, and is associated with prolonged ICU and hospital stay and increased healthcare utilization. Intravenous amiodarone is commonly used for POAF treatment but may increase the risk of catheter-related infection. Colchicine, an anti-inflammatory and immunomodulatory agent, has shown potential to reduce postpericardiotomy syndrome and POAF in small-scale studies, but existing evidence remains inconsistent, and most prior trials did not distinguish between surgical strategies.

In this trial, 400 adult patients undergoing elective CABG will be enrolled and randomized in a 1:1 ratio within each stratum (OPCAB and ONCAB) to receive either colchicine or placebo. The treatment group will receive colchicine 0.5 mg orally twice daily, starting on postoperative day -3 and continuing through postoperative day 7. The placebo group will receive identically appearing tablets on the same schedule.

The primary endpoint is the incidence of new-onset atrial fibrillation within 14 days after surgery, defined as any episode lasting ≥30 seconds documented by 12-lead ECG, continuous telemetry, or Holter monitoring.

Secondary outcomes include the incidence and management of other arrhythmias (atrial flutter, supraventricular tachycardia), total dose and duration of intravenous amiodarone, ICU and total hospital length of stay, ischemic stroke or TIA, infection events (including catheter-related infection), and 30-day readmission. Safety outcomes will include gastrointestinal intolerance, hepatic enzyme elevation, creatine kinase elevation with myalgia, hematologic abnormalities, and serious adverse events (SAE).

Pharmacokinetic (PK) and pharmacodynamic (PD) analyses will measure colchicine concentrations in plasma and pericardial fluid and correlate these with inflammatory biomarkers (CRP, IL-6, TNF-α, white blood cell profile, and immune cell phenotyping by flow cytometry). This integrated approach aims to elucidate the relationship between colchicine exposure, inflammation, and POAF occurrence.

Statistical analyses will primarily follow an intention-to-treat (ITT) approach. The primary endpoint will be evaluated using a log-binomial or Poisson-robust model to estimate relative risk (RR) with 95% confidence intervals, including treatment, surgical strategy, and their interaction terms. Time-to-event outcomes will be analyzed using Cox proportional hazards or Kaplan-Meier methods, and continuous variables by linear mixed-effects models. Missing data will be handled conservatively with multiple imputation where appropriate. An independent Data and Safety Monitoring Board (DSMB) will review blinded safety data once 50% of subjects have been enrolled.

The trial is expected to clarify the pharmacokinetic and clinical effects of colchicine in different CABG surgical strategies. If colchicine is shown to effectively reduce POAF in OPCAB patients or in those achieving sufficient plasma concentrations, it may provide a simple, low-cost preventive strategy that reduces the need for intravenous amiodarone, lowers infection risk, and shortens ICU and hospital stay. The results could guide future optimization of dosing and timing strategies in ONCAB patients and improve perioperative management and resource utilization in cardiac surgery.

03

Conditions studied

  • Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)

Browse trials for

Keywords

  • colchicine
  • postoperative atrial fibrillation
  • coronary artery bypass grafting
  • off-pump surgery
  • cardiopulmonary bypass
  • pharmacokinetics
  • inflammation
  • neutrophil extracellular traps
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 years or older scheduled to undergo elective coronary artery bypass grafting (CABG), including either off-pump CABG or on-pump CABG.
  • Ability to receive oral study medication before and after surgery.
  • Provision of written before randomization.

Exclusion criteria

Exclusion Criteria:

  • History of atrial fibrillation or atrial flutter before surgery.
  • Severe renal impairment (estimated \<30 mL/min/1.73 m²) or chronic dialysis.
  • Severe hepatic dysfunction.
  • Known or previous severe adverse reaction to colchicine.
  • Pregnancy or breastfeeding.
  • Current use of strong or P-glycoprotein inhibitors that cannot be safely discontinued or substituted.
  • Any condition judged by the investigators to interfere with study participation or safety assessment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Colchicine Group

    Participants will receive colchicine 0.5 mg orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).

    Drug: Colchicine 0.5 MG oral tablet twice daily

  • Placebo comparator
    Placebo Group

    Participants will receive an identically appearing placebo tablet orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).

    Drug: Placebo Oral Tablet

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine 0.5 mg administered orally twice daily beginning 3 days before surgery and continuing through postoperative day 7. Temporary interruption or discontinuation is permitted for clinically significant adverse events according to the study safety protocol.

  • DrugPlacebo Oral Tablet

    Matching placebo tablet administered orally twice daily beginning 3 days before surgery and continuing through postoperative day 7 under double-blind conditions.

06

What researchers measure

Primary outcomes

  1. Percentage change in plasma colchicine concentration following initiation of cardiopulmonary bypass in the ONCAB stratum

    Percentage change in plasma colchicine concentration measured 20-30 minutes after initiation of cardiopulmonary bypass (CPB) relative to the pre-anesthesia induction baseline in participants receiving colchicine in the on-pump coronary artery bypass grafting (ONCAB) stratum. Plasma colchicine concentrations will be quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This endpoint will be assessed using within-participant paired comparisons.

    Time frame: From before anesthesia induction to 20-30 minutes after initiation of cardiopulmonary bypass on the day of surgery.

  2. Incidence of new-onset atrial fibrillation or atrial flutter within 14 days after OPCAB surgery

    Proportion of participants in the off-pump coronary artery bypass grafting (OPCAB) stratum who develop new-onset atrial fibrillation (AF) or atrial flutter (AFL) lasting ≥30 seconds, documented by 12-lead ECG, continuous telemetry monitoring, or 24-hour Holter recording within 14 days after surgery. The incidence will be compared between the colchicine and placebo groups. Events will be adjudicated by blinded cardiologists according to prespecified criteria.

    Time frame: From the day of surgery through postoperative day 14.

Secondary outcomes

  1. Total duration of postoperative atrial fibrillation or atrial flutter

    Cumulative duration (in hours) of all documented atrial fibrillation or atrial flutter episodes within 14 days after CABG surgery.

    Time frame: From the day of surgery through postoperative day 14.

  2. Proportion of participants requiring cardioversion for postoperative atrial fibrillation or atrial flutter

    Percentage of participants who undergo pharmacologic or electrical cardioversion for postoperative atrial fibrillation or atrial flutter within 14 days after CABG surgery.

    Time frame: From the day of surgery through postoperative day 14.

  3. Cumulative dose of intravenous amiodarone used for POAF treatment

    Total cumulative intravenous amiodarone dose (mg) administered for the treatment of postoperative atrial fibrillation or atrial flutter within 14 days after CABG surgery.

    Time frame: From the day of surgery through postoperative day 14.

  4. Length of stay in the intensive care unit (ICU)

    Duration of postoperative intensive care unit (ICU) stay, measured in days, from postoperative ICU admission until ICU discharge or death, whichever occurs first.

    Time frame: From postoperative ICU admission until ICU discharge or death, whichever occurs first, assessed up to 30 days after surgery.

  5. Total hospital length of stay

    Total number of days from hospital admission for CABG surgery until hospital discharge.

    Time frame: From hospital admission until hospital discharge or death, whichever occurred first, assessed up to 60 days after surgery.

  6. 30-day hospital readmission

    Incidence of unplanned hospital readmission for any cause within 30 days after discharge from index CABG hospitalization.

    Time frame: From hospital discharge until 30 days after discharge.

  7. Plasma and pericardial fluid colchicine concentrations

    Measured colchicine concentrations (ng/mL) in plasma and pericardial fluid at predefined perioperative time points(preoperative baseline, end of surgery, postoperative day 1, postoperative day 3, and postoperative day 7)for pharmacokinetic analysis.

    Time frame: From preoperative day 1 through postoperative day 7.

07

Study locations

1 site
08

References and documents

Publications

  • Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, Ferrua S, Belli R, Maestroni S, Simon C, Zingarelli E, Barosi A, Sansone F, Patrini D, Vitali E, Trinchero R, Spodick DH, Adler Y; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011 Nov 22;124(21):2290-5. doi: 10.1161/CIRCULATIONAHA.111.026153. Epub 2011 Nov 16. PubMed 22090167 ↗
  • Zhao H, Chen Y, Mao M, Yang J, Chang J. A meta-analysis of colchicine in prevention of atrial fibrillation following cardiothoracic surgery or cardiac intervention. J Cardiothorac Surg. 2022 Sep 1;17(1):224. doi: 10.1186/s13019-022-01958-9. PubMed 36050741 ↗
  • Wang MX, Deng XL, Mu BY, Cheng YJ, Chen YJ, Wang Q, Huang J, Zhou RW, Huang CB. Effect of colchicine in prevention of pericardial effusion and atrial fibrillation: a meta-analysis. Intern Emerg Med. 2016 Sep;11(6):867-76. doi: 10.1007/s11739-016-1496-5. Epub 2016 Jul 4. PubMed 27378573 ↗

Individual participant data

Plan to share: No — The individual participant data (IPD) collected in this study will not be shared because they include sensitive clinical and biological information linked to hospital medical records. Data sharing is restricted by institutional and national privacy regulations. Only de-identified, aggregate summary data will be available in publications or presentations after study completion.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 30 phase 2/3 interventional studies under Inflammation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 29 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2028 → Dec 2028 and completion Jul 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
May 28, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Dec 2028was Jul 2028
CompletionEst.
Dec 2028was Jul 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2028→Dec 2028
Nov 17, 2026
Study completion
Jul 2028→Dec 2028
Nov 17, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedIncidence of new-onset atrial fibrillation or atrial flutter within 14 days after CABGOPCAB surgeryTime frame: From the day of surgery through postoperative day 14.
  • AddedPercentage change in plasma colchicine concentration following initiation of cardiopulmonary bypass in the ONCAB stratumTime frame: From before anesthesia induction to 20-30 minutes after initiation of cardiopulmonary bypass on the day of surgery.
Nov 17, 2026
Secondary outcomes
3 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedTotal duration of post-operativepostoperative atrial fibrillation (POAF)or atrial flutterTime frame: From the day of surgery through postoperative day 14.
  • EditedProportion of patientsparticipants requiring cardioversion for POAFpostoperative atrial fibrillation or atrial flutterTime frame: From the day of surgery through postoperative day 14.
  • EditedTotalCumulative dose of intravenous amiodarone used for POAF treatmentTime frame: From the day of surgery through postoperative day 14.
  • Time frameLength of stay in the intensive care unit (ICU)From the date of surgery until discharge from the intensive care unit or death, whichever occurred first, assessed up to 30 days after surgery. → From postoperative ICU admission until ICU discharge or death, whichever occurs first, assessed up to 30 days after surgery.
  • DescriptionLength of stay in the intensive care unit (ICU): how it is measured was reworded
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Jul 2028→Dec 2028
    Study completion Jul 2028→Dec 2028
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedIncidence of new-onset atrial fibrillation or atrial flutter within 14 days after CABGOPCAB surgeryTime frame: From the day of surgery through postoperative day 14.
    • AddedPercentage change in plasma colchicine concentration following initiation of cardiopulmonary bypass in the ONCAB stratumTime frame: From before anesthesia induction to 20-30 minutes after initiation of cardiopulmonary bypass on the day of surgery.
    Secondary outcomes 3 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedTotal duration of post-operativepostoperative atrial fibrillation (POAF)or atrial flutterTime frame: From the day of surgery through postoperative day 14.
    • EditedProportion of patientsparticipants requiring cardioversion for POAFpostoperative atrial fibrillation or atrial flutterTime frame: From the day of surgery through postoperative day 14.
    • EditedTotalCumulative dose of intravenous amiodarone used for POAF treatmentTime frame: From the day of surgery through postoperative day 14.
    • Time frameLength of stay in the intensive care unit (ICU)From the date of surgery until discharge from the intensive care unit or death, whichever occurred first, assessed up to 30 days after surgery. → From postoperative ICU admission until ICU discharge or death, whichever occurs first, assessed up to 30 days after surgery.
    • DescriptionLength of stay in the intensive care unit (ICU): how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07611019
Responsible party
National Taiwan University Clinical Trial Center (Attending Physician, National Taiwan University Hospital) — Principal investigator
First posted
May 28, 2026
Start date
Jul 6, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion